JP2018530574A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018530574A5 JP2018530574A5 JP2018518654A JP2018518654A JP2018530574A5 JP 2018530574 A5 JP2018530574 A5 JP 2018530574A5 JP 2018518654 A JP2018518654 A JP 2018518654A JP 2018518654 A JP2018518654 A JP 2018518654A JP 2018530574 A5 JP2018530574 A5 JP 2018530574A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- antibody
- composition according
- antigen
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 24
- 239000012634 fragment Substances 0.000 claims 14
- 239000000427 antigen Substances 0.000 claims 13
- 102000036639 antigens Human genes 0.000 claims 13
- 108091007433 antigens Proteins 0.000 claims 13
- 206010064930 age-related macular degeneration Diseases 0.000 claims 5
- 208000002780 macular degeneration Diseases 0.000 claims 5
- 229960002224 eculizumab Drugs 0.000 claims 4
- 208000005590 Choroidal Neovascularization Diseases 0.000 claims 3
- 206010060823 Choroidal neovascularisation Diseases 0.000 claims 3
- 210000001744 T-lymphocyte Anatomy 0.000 claims 3
- 206010061218 Inflammation Diseases 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 210000000952 spleen Anatomy 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 210000000068 Th17 cell Anatomy 0.000 claims 1
- 208000000208 Wet Macular Degeneration Diseases 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 230000004304 visual acuity Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562238483P | 2015-10-07 | 2015-10-07 | |
| US62/238,483 | 2015-10-07 | ||
| PCT/US2016/055794 WO2017062649A1 (en) | 2015-10-07 | 2016-10-06 | A method for treating age-related macular degeneration in a patient |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018530574A JP2018530574A (ja) | 2018-10-18 |
| JP2018530574A5 true JP2018530574A5 (OSRAM) | 2019-11-14 |
Family
ID=57200105
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018518654A Pending JP2018530574A (ja) | 2015-10-07 | 2016-10-06 | 患者の加齢黄斑変性を治療する方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US11203634B2 (OSRAM) |
| EP (1) | EP3359566A1 (OSRAM) |
| JP (1) | JP2018530574A (OSRAM) |
| WO (1) | WO2017062649A1 (OSRAM) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY191668A (en) | 2016-06-14 | 2022-07-06 | Regeneron Pharma | Anti-c5 antibodies and uses thereof |
| JP2021506241A (ja) | 2017-12-13 | 2021-02-22 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 抗ｃ５抗体組み合わせ物およびその使用 |
| US20190247560A1 (en) | 2018-02-13 | 2019-08-15 | Gambro Lundia Ab | Extracorporeal devices and methods of treating complement factor related diseases |
| GB201905810D0 (en) * | 2019-04-25 | 2019-06-05 | Volution Immuno Pharmaceuticals Sa | Method of treatment |
| CN113754763B (zh) * | 2020-06-05 | 2024-03-08 | 天辰生物医药(苏州)有限公司 | 分离的抗原结合蛋白及其用途 |
| EP4397306A1 (en) * | 2023-01-05 | 2024-07-10 | Dompe' Farmaceutici S.P.A. | C5ar1 inhibitors for use in the treatment of ocular mucous membrane pemphigoid and/or oral mucous membrane pemphigoid |
| WO2024238867A1 (en) * | 2023-05-16 | 2024-11-21 | Regenxbio Inc. | Vectorized anti-complement antibodies and administration thereof |
| TW202525324A (zh) * | 2023-08-17 | 2025-07-01 | 大陸商信達生物製藥（蘇州）有限公司 | 治療年齡相關性黃斑變性和糖尿病性黃斑水腫的方法 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
| US5525491A (en) | 1991-02-27 | 1996-06-11 | Creative Biomolecules, Inc. | Serine-rich peptide linkers |
| EP0512733A2 (en) | 1991-05-03 | 1992-11-11 | Washington University | Modified complement system regulator |
| ATE419355T1 (de) | 1992-02-06 | 2009-01-15 | Novartis Vaccines & Diagnostic | Marker für krebs und biosynthetisches bindeprotein dafür |
| US6005079A (en) | 1992-08-21 | 1999-12-21 | Vrije Universiteit Brussels | Immunoglobulins devoid of light chains |
| EP0656946B2 (en) | 1992-08-21 | 2010-03-31 | Vrije Universiteit Brussel | Immunoglobulins devoid of light chains |
| DE69427974T2 (de) | 1993-04-29 | 2001-12-06 | Unilever N.V., Rotterdam | Herstellung von antikörpern oder funktionstüchtig gemachten teilen davon, abgeleitet von schweren ketten von immunglobulinen von camelidae |
| US6074642A (en) | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| KR100508289B1 (ko) | 1998-04-21 | 2005-08-17 | 마이크로메트 에이지 | Ｃｄ１９×ｃｄ３ 특이 폴리펩티드 및 그의 용도 |
| ITMI20021527A1 (it) | 2002-07-11 | 2004-01-12 | Consiglio Nazionale Ricerche | Anticorpi anti componente c5 del complemento e loro uso |
| US9415102B2 (en) * | 2002-09-06 | 2016-08-16 | Alexion Pharmaceuticals, Inc. | High concentration formulations of anti-C5 antibodies |
| US8454963B2 (en) | 2003-11-13 | 2013-06-04 | Musc Foundation For Research Development | Tissue targeted complement modulators |
| AU2006236439B2 (en) | 2005-04-15 | 2012-05-03 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| TWI323734B (en) | 2005-08-19 | 2010-04-21 | Abbott Lab | Dual variable domain immunoglobulin and uses thereof |
| WO2007076062A2 (en) | 2005-12-21 | 2007-07-05 | Wyeth | Protein formulations with reduced viscosity and uses thereof |
| DK2359834T5 (en) | 2006-03-15 | 2017-02-06 | Alexion Pharma Inc | Treatment of paroxysmal nocturnal hemoglobinuria patients with a complement inhibitor |
| WO2010015608A1 (en) | 2008-08-05 | 2010-02-11 | Novartis Ag | Compositions and methods for antibodies targeting complement protein c5 |
| KR101800913B1 (ko) * | 2010-04-30 | 2017-12-20 | 알렉시온 파마슈티칼스, 인코포레이티드 | 항-c5a 항체들과 이 항체들을 이용하는 방법 |
| TW201241008A (en) * | 2010-10-01 | 2012-10-16 | Alexion Pharma Inc | Polypeptides that bind to human complement component C5 |
| TWI803876B (zh) | 2011-03-28 | 2023-06-01 | 法商賽諾菲公司 | 具有交叉結合區定向之雙重可變區類抗體結合蛋白 |
| NZ631007A (en) * | 2014-03-07 | 2015-10-30 | Alexion Pharma Inc | Anti-c5 antibodies having improved pharmacokinetics |
-
2016
- 2016-10-06 JP JP2018518654A patent/JP2018530574A/ja active Pending
- 2016-10-06 EP EP16785620.2A patent/EP3359566A1/en not_active Withdrawn
- 2016-10-06 WO PCT/US2016/055794 patent/WO2017062649A1/en not_active Ceased
- 2016-10-06 US US15/766,753 patent/US11203634B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018530574A5 (OSRAM) | ||
| ES2968255T3 (es) | Anticuerpos anti-péptidos beta amiloides N3-beta-glu y usos de los mismos | |
| JP2016528247A5 (OSRAM) | ||
| TWI705827B (zh) | 治療眼部疾病之方法 | |
| TWI848905B (zh) | 用於治療補體介導之疾病及病症之方法 | |
| JP2017042172A5 (OSRAM) | ||
| JP2010528047A5 (OSRAM) | ||
| WO2008154251A4 (en) | C3b antibodies and methods for the prevention and treatment of complement- associated disorders | |
| JP2017515811A5 (OSRAM) | ||
| RU2009147744A (ru) | Профилактика и лечение патологических состояний глаз, вызванных комплементом | |
| JP2011504872A5 (OSRAM) | ||
| CN117024583A (zh) | 抗N3pGlu淀粉状蛋白β肽抗体及其用途 | |
| EA201000787A1 (ru) | Антигенсвязывающие белки | |
| JP2016504416A5 (OSRAM) | ||
| JP2015503909A5 (OSRAM) | ||
| NZ585110A (en) | Method and compositions for diagnosis and treatment of amyloidosis | |
| JP2018505882A5 (OSRAM) | ||
| RU2018119014A (ru) | АНТИТЕЛА ПРОТИВ Нtr1 И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
| JP2019510078A5 (OSRAM) | ||
| US11732046B2 (en) | Modified anti-PD-L1 antibody and methods and uses for treating a neurodegenerative disease | |
| JP2018529661A5 (OSRAM) | ||
| JP2017534645A5 (OSRAM) | ||
| JP2018512402A5 (OSRAM) | ||
| JP2009519025A5 (OSRAM) | ||
| JP2011503094A5 (OSRAM) |